Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group

Figure 4

Subgroup analyses. Forest plots illustrating hazard ratio (HR) estimates of treatment effect with 95% confidence intervals (CI) for (A) time to progression and (B) overall survival comparison between patients with TIMP-1 negative and TIMP-1 positive tumors, basal-like and non-basal-like tumors, TIMP-1 negative and/or basal-like (G responsive) and TIMP-1 positive and non-basal-like tumors (G nonresponsive). Abbreviations: D = docetaxel; G = gemcitabine; TIMP-1 = tissue inhibitor of metalloproteinases-1.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us